Trandolapril/verapamil
| Combination of | |
|---|---|
| Trandolapril | Calcium channel blocker |
| Verapamil | ACE inhibitor |
| Clinical data | |
| Trade names | Tarka |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Trandolapril/verapamil (Tarka)[2] is an oral antihypertensive medication that combines a slow release formulation of verapamil hydrochloride, a calcium channel blocker, and an immediate release formulation of trandolapril, an ACE inhibitor. The patent, held by Abbott Laboratories, expired on February 24, 2015.
This combination medication contains angiotensin-converting enzyme (ACE) inhibitor and calcium channel blocker and is prescribed for high blood pressure.
References
External links
- "Trandolapril mixture with verapamil hydrochloride". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.